Skip to content

Tracking Artemisinin Resistance in India.

A multicentrec trial to detect in vivo resistance of Plasmodium falciparum to artesunate in patients with uncomplicated malaria. - TRAC-India

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/10/006243
Enrollment
140
Registered
2015-10-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Uncomplicated Plasmodium falciparum malaria

Interventions

Intervention1: Artesuante tablets plus ACT : Artesuante 4mg per kg body weight Oral on Day0 Artesuante 4mg per kg body weight Oral on Day1 Artesuante 4mg per kg body weight Oral on Day2 followed by

Sponsors

National Institute of Malaria ResearchICMR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with asexual forms of P. falciparum Asexual P. falciparum parasitaemia: 10,000 to 100,000/uL, determined on a thin or thick blood film Fever defined as > 37.5°C temperature or a history of fever within the last 24 hours Written informed consent (by legally acceptable representative in case of children) Willingness and ability of the patients/guardians to comply with the study protocol for the duration of the study

Exclusion criteria

Exclusion criteria: Signs of severe/complicated malaria Haematocrit Acute illness other than malaria requiring treatment For females: pregnancy, lactating Patients who have received artemisinin or a derivative or an artemisinin-containing combination therapy (ACT) within the previous 7 days History of allergy or known contraindication to artemisinins, or to the ACT to be used at the site Previous splenectomy

Design outcomes

Primary

MeasureTime frame
Within one year the study is expected to produce data of the prevalence and severity of artemisinin resistance if any.Fro this Parasite clearrance time PCT will be calculated.Timepoint: 28 days followup

Secondary

MeasureTime frame
Parasite reduction rates and ratios at 24 and 48 hours by microscopy and quantitative PCR Time for parasite count to fall to 50%, 90% and 99% of initial parasite density Fever clearance time Proportion of patients with gametocytemia before, during and after treatment with artesunate, assessed at admission, on days 3, 7 and 14 Parasite molecular markers of drug resistanceTimepoint: 28 days follow up

Countries

India

Contacts

Public ContactDr Neena Valecha

National Institute of Malaria Research

neelima.nimr@gmail.com01125307333

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026